Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.


Alefacept Product Approval Information - Licensing Action 1/30/03

Proper name: Alefacept
Tradename: Amevive
Manufacturer: Biogen, Inc, Cambridge, MA, License #1204
Indication for Use: Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy
Approval Date: 1/30/2003
Type of submission: Biologics license application


Label (PDF)

Clinical Pharmacology Review - (PDF)

Clinical Review - (PDF Part 2)

CMC Review - (PDF)

Pharmacology and Toxicology Review - (PDF)

Page Last Updated: 09/30/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English